Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatmentsCreating a data exchange strategy for radiotherapy research: towards federated databases and anonymised public datasetsExploring the role of cancer stem cells in radioresistanceβ₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapyImmunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data.Radiogenomics: radiobiology enters the era of big data and team science.Predictive factors in radiotherapy for non-small cell lung cancer: present status.Impact of the tumour bed effect on microenvironment, radiobiological hypoxia and the outcome of fractionated radiotherapy of human FaDu squamous-cell carcinoma growing in the nude mouse.Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.Experimental evaluation of functional imaging for radiotherapy.Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results.Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas.Core needle biopsies for determination of the microenvironment in individual tumours for longitudinal radiobiological studies.Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts.Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts.Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control.PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alphaMonitoring PAI-1 and VEGF levels in 6 human squamous cell carcinoma xenografts during fractionated irradiation.Radiobiological effectiveness of laser accelerated electrons in comparison to electron beams from a conventional linear accelerator.Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer.BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenograftsEffect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts.EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.Establishment of a small animal tumour model for in vivo studies with low energy laser accelerated particlesBe smart against cancer! A school-based program covering cancer-related risk behaviorComparison study of in vivo dose response to laser-driven versus conventional electron beam.Updated European core curriculum for radiotherapists (radiation oncologists). Recommended curriculum for the specialist training of medical practitioners in radiotherapy (radiation oncology) within Europe.Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review.Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results.Molecular targeting in radiotherapy of lung cancer.Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.Correlation of FMISO simulations with pimonidazole-stained tumor xenografts: A question of O2 consumption?HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCCImproving external beam radiotherapy by combination with internal irradiationRegional radiotherapy in high-risk breast cancer: is the issue solved?Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy.TCP and NTCP: a basic introduction.TCP and NTCP in preclinical and clinical research in Europe.Influence of connective tissue diseases on the expression of radiation side effects: a systematic review.
P50
Q26766132-1B771D66-6DBD-4387-B168-BF45FA99D339Q26864472-1CC910A9-89A2-431D-99B1-FA61B53010A0Q28282037-8e258cf0-40ca-ed4a-9c3b-72abf5029e76Q30427521-64D4EC31-5A07-49FB-8622-C786AFE80302Q30724365-C1C7F8A9-871B-4887-9A1D-F01036B93E64Q30833608-6150AB53-710B-44CA-A88C-9C18B06258F1Q31857384-3A679465-67E8-4E62-8533-168D47C4E68FQ33183182-3405B98D-0E2B-47CA-B7CA-BCF0BF11A9FFQ33276384-F9334557-4F8E-4039-B2D8-1FCAFEE0557EQ33312903-23A092B5-FB8F-4BC3-9901-7FEA13FE9A33Q33353609-11E00F3A-B74F-43E6-B4D0-C6D6E3AB4A48Q33438005-87279E3C-78E0-42F2-A652-90B695D80E02Q33493641-B029BF80-90FE-46E0-BDAF-D4271F9A229DQ33515391-F50E0B58-1F21-46FC-95A8-EFE9F9F901DBQ33871885-69C3279F-FCA5-41F5-BD67-D49536B62EC0Q33887017-80C9A82C-CCFB-4C4A-9618-D7204AD92AD4Q33968025-F7E31DB3-9325-4E55-8A7D-78D2CC20ECE1Q34300139-A3CE5A05-32B8-413D-A8AC-0E6F2A26541FQ34319085-A5F74F0B-911C-449B-9835-D6D95EE9BCEFQ34323959-8EBD694E-53AD-4116-AB1B-686E6F886EC6Q34384415-7E34E451-7EFB-4325-A601-229A0B17F64AQ34672437-9D78B412-AE12-422E-9650-AD53C30634A5Q34740289-3AEEF1D4-54C0-43F0-AD8A-E14D45F45790Q34782417-879433EA-0A16-4CD7-97E2-31FFB785F4C9Q35095806-95E111F4-BBBE-45EA-82EF-35AAFB35C605Q35155621-3F01C7F9-69D4-4685-9777-6F8F9BA2EADEQ35544761-329C7AD3-69E8-48AF-A553-8AC52EE96549Q35694685-9EF88395-1A46-4301-A76C-73DDE99ECCD2Q35827651-00A75EF6-98DC-462B-A909-C148CCD58A69Q35902858-0D4D087D-8B7B-46BC-85C1-6811B00EC3ADQ35955505-73917026-1179-46FD-BA34-6598FA3275ADQ36010006-BD7A52E8-4034-4EF0-B23D-ED6509491E66Q36066409-34469932-3121-486F-AF0A-7ECE7F83C23CQ36204937-6CD16607-D329-4DFC-A9E5-63AFC1984B73Q36235732-532FE50C-6108-4E04-BA50-195DA86D8A6BQ36235737-87ABAE73-D4A7-497C-B634-68A2D4053AA2Q36300626-93B66429-F7B7-42BD-A451-ABF1F3485ED3Q36315744-3B236A15-F7F9-4795-A501-FBE2EF8D6157Q36315760-C3D2A6E4-8794-4AC6-A180-9908E69E332EQ36381603-64DD9FC1-D697-4554-82F9-78DD9797C5D2
P50
description
Duits onderzoeker
@nl
deutscher Mediziner
@de
researcher ORCID ID = 0000-0002-9340-974X
@en
name
Michael Baumann (Mediziner)
@de
Michael Baumann
@ast
Michael Baumann
@en
Michael Baumann
@es
Michael Baumann
@nl
Michael Baumann
@sl
type
label
Michael Baumann (Mediziner)
@de
Michael Baumann
@ast
Michael Baumann
@en
Michael Baumann
@es
Michael Baumann
@nl
Michael Baumann
@sl
prefLabel
Michael Baumann (Mediziner)
@de
Michael Baumann
@ast
Michael Baumann
@en
Michael Baumann
@es
Michael Baumann
@nl
Michael Baumann
@sl
P108
P214
P227
P244
P106
P108
P1153
7202494765
P1871
cnp00799104
P19
P21
P214
P227
P244
no2016031565
P2456
P31
P496
0000-0002-9340-974X
P5008
P569
1962-12-02T00:00:00Z